Market Demand Significant unmet need in allergy diagnostics and disease-modifying treatment with only a small fraction of affected individuals currently treated. This creates a broad addressable market for Allergychoices’ home-based treatment model and ACP programs, with potential expansion into employer-based health and onsite clinic partnerships.

Strategic Partnerships Opportunity to scale via the Allergy Control Program with employers, benefits consultants, onsite/near-site clinics, and Direct Primary Care providers. Focus on reducing hidden costs of allergic disease, improving productivity, and simplifying treatment to drive B2B sales and channel partnerships.

Clinical Advantage La Crosse Method protocols offer a long-standing, home-based, disease-modifying approach that can be marketed as a differentiated, convenient solution with fewer office visits. Emphasize competitive positioning against traditional allergy care by highlighting root-cause treatment and multi-condition impact (asthma, eczema, sinusitis).

Digital & Ops Readiness Existing tech stack (Google Ads, tracking, Hotjar, Calendly, WordPress, OneTrust, Microsoft 365) supports scalable marketing, scheduling, and compliance. Leverage digital channels for lead generation, nurture campaigns, and patient/provider onboarding to accelerate sales cycles.

Growth Signals Revenue in the multi-million range with recent recognition as a national finalist for a Health Value Award signals credibility and traction. Target mid-market healthcare systems and physician groups similar to listed peers to maximize referenceability and credibility in bids and proposals.